A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

NCT02029430 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Kaposi's Sarcoma
HIV Positive
AIDS

Interventions

DRUG: 50 mg/m2 aldoxorubicin
DRUG: 100 mg/m2 aldoxorubicin
DRUG: 150 mg/m2 aldoxorubicin

Sponsor

ImmunityBio, Inc.